Amendment: SEC Form S-4/A filed by Movano Inc.
$MOVE
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
S-1/A - Movano Inc. (0001734750) (Filer)
S-4/A - Movano Inc. (0001734750) (Filer)
425 - Movano Inc. (0001734750) (Subject)
Filed by Movano Inc.pursuant to Rule 425 under the Securities Act of 1933and deemed filed pursuant to Rule 14a-12under the Securities Exchange Act of 1934Subject Company: Movano Inc.Commission File No.: 001-40254Date: January 22, 2026 ARLINGTON, Va., Jan. 22, 2026 /PRNewswire/ -- Corvex, Inc., an AI cloud computing company specializing in GPU-accelerated infrastructure for AI workloads, today announced a long-term GPU lease agreement with an established AI-driven provider of high-performance battery technologies. The deployment, a dedicated cluster of NVIDIA H200 GPUs, will underpin the customer's core AI development and research initiatives, including proprietary algorithms. The customer s
Shares Expected to Begin Trading on Split-Adjusted Basis on October 10, 2025 PLEASANTON, Calif., Oct. 8, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today that it will implement a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on October 10, 2025. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Friday, October 10, 2025, and will continue to trade on The Nasdaq Capital Market under the symbol "MOVE." The new CUSIP number for the common stock will be 62459M 305.
PLEASANTON, Calif., Aug. 28, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that, by letter received on August 27, 2025, the Nasdaq Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq") has determined to grant the Company's request to continue its listing on Nasdaq, subject to (i) the Company regaining compliance with Listing Rule 5250(c)(1), requiring the timely filing of periodic reports (the "Period Filing Rule"), by filing its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025 on or before September 30, 2025, and (ii) the Company demonstrating compliance with Listing Rule 5550(a)(2), requiring the main
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto
Prepares for September 17, 2024, Evie Ring back in stock dateAnnounces brand partnership with digital creator Heidi D'AmelioFocuses on launch of EvieMED and securing B2B opportunitiesConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Aug. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update. Following the successful close of the Company's April 2024 $24.1 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device
Company continues to work with FDA to bring this pioneering healthcare product to market PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) plans to meet with the FDA in mid-August, as part of the Company's ongoing process to secure a 510(k) clearance for the EvieMED Ring, a wearable designed to not only provide medical device functionality through its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity and mood/energy/symptom logging. On April 21, 2024, Movano Health filed an updated 510(k) for the EvieMED Ring's pulse oximetry feature. At the time of the filing and based on prior interactions with the agency and its protoco
SC 13G - Movano Inc. (0001734750) (Subject)
SC 13G/A - Movano Inc. (0001734750) (Subject)
SC 13G - Movano Inc. (0001734750) (Subject)